Replimune Group Target of Unusually High Options Trading (NASDAQ:REPL)

Replimune Group, Inc. (NASDAQ:REPL) was the target of some unusual options trading on Tuesday. Traders acquired 5,831 put options on the company. This represents an increase of approximately 163% compared to the average volume of 2,217 put options.

Insider Activity at Replimune Group

In other Replimune Group news, insider Pamela Esposito sold 18,600 shares of the stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $20.01, for a total transaction of $372,186.00. Following the transaction, the insider now owns 263,436 shares in the company, valued at approximately $5,271,354.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders have sold 25,358 shares of company stock worth $507,400. Company insiders own 20.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in REPL. State Street Corp grew its holdings in Replimune Group by 96.3% during the first quarter. State Street Corp now owns 2,904,354 shares of the company’s stock valued at $51,291,000 after purchasing an additional 1,424,810 shares during the period. Price T Rowe Associates Inc. MD raised its position in Replimune Group by 21.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,064,744 shares of the company’s stock valued at $137,761,000 after purchasing an additional 893,573 shares during the period. BVF Inc. IL grew its stake in shares of Replimune Group by 40.7% during the first quarter. BVF Inc. IL now owns 2,143,036 shares of the company’s stock valued at $37,846,000 after buying an additional 620,407 shares during the last quarter. BlackRock Inc. grew its stake in shares of Replimune Group by 20.3% during the first quarter. BlackRock Inc. now owns 3,622,104 shares of the company’s stock valued at $63,966,000 after buying an additional 611,552 shares during the last quarter. Finally, Marshall Wace LLP grew its stake in shares of Replimune Group by 90.6% during the second quarter. Marshall Wace LLP now owns 1,233,224 shares of the company’s stock valued at $28,635,000 after buying an additional 586,336 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright lowered their target price on Replimune Group from $51.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, August 7th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $51.60.

Replimune Group Price Performance

Shares of REPL stock opened at $10.83 on Wednesday. The firm has a market cap of $638.97 million, a P/E ratio of -3.65 and a beta of 1.63. Replimune Group has a fifty-two week low of $10.79 and a fifty-two week high of $29.52. The business’s 50 day moving average price is $16.32 and its 200-day moving average price is $18.98. The company has a debt-to-equity ratio of 0.10, a quick ratio of 17.06 and a current ratio of 17.06.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.